Unicycive to Present at JMP Securities Life Sciences Conference
Presentation to highlight Company’s novel treatments for kidney diseases
LOS ALTOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will participate in the JMP Securities Life Sciences Conference taking place June 15-16, 2022 in New York as follows:
JMP Securities Life Sciences Conference
- Dates: June 15-16, 2022
- Location: New York City
- Company Presentation: June 16, 2022 at 10:30 am ET
- Presenter: Dr. Shalabh Gupta
Dr. Gupta’s presentation at the JMP Securities Life Sciences conference will be webcast live and archived in the Investor Relations section of the Company’s website here.
To schedule a one-on-one meeting with Unicycive, please contact your JMP Securities’ representative. For questions or further information about Unicycive, please contact Anne Marie Fields of Stern IR at 212-362-1200 or submit your request to email@example.com.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.
Stern Investor Relations
SOURCE: Unicycive Therapeutics, Inc.
Released June 6, 2022